Domestic pharmaceutical companies focus on development of salt-modified drugs and generics of ‘Viread’
The hepatitis B therapy which recorded KRW 125.3 billion prescriptions in Korea last year, Viread(generic name: tenofovir, Gilead), will be expired in patent. Thus, pharmaceutical companies preparing for generics related to the drug are getting busier as well.
Domestic companies are getting read...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
